Table 1.
GO analysis of changes in Wnt1-mediated gene expression reveals time-specific enrichment. (A) Selected KEGG pathways (129) or (B) selected highest-level (level 5) GO biological processes showing significant categorical enrichment at each time point (FDR ≤5%). GO analysis was performed in DAVID (40) on all significantly changed genes (t test, P ≤ 0.05), irrespective of the direction of the change. ATP, adenosine triphosphate; ncRNA, noncoding RNA; MAPK, mitogen-activated protein kinase; GTPase, guanosine triphosphatase; VEGF, vascular endothelial growth factor
| A |
B |
||||
|---|---|---|---|---|---|
| KEGG pathway | P | GO biological process level 5 | P | ||
| 2 Hours | Alzheimer’s disease | 1.47 × 10−6 | 2 Hours | RNA splicing | 7.95 × 10−9 |
| Chronic myeloid leukemia | 1.15 × 10−5 | mRNA processing | 9.72 × 10−9 | ||
| Colorectal cancer | 4.00 × 10−5 | Regulation of transcription, DNA-dependent | 7.79 × 10−6 | ||
| Huntington’s disease | 5.36 × 10−5 | ATP synthesis coupled proton transport | 1.10 × 10−4 | ||
| Oxidative phosphorylation | 9.16 × 10−5 | Energy coupled proton transport | 1.10 × 10−4 | ||
| Pyrimidine metabolism | 1.11 × 10−4 | Regulation of neuron projection development | 1.64 × 10−4 | ||
| Parkinson’s disease | 1.18 × 10−4 | Regulation of ubiquitin-protein ligase activity | 2.33 × 10−4 | ||
| Pancreatic cancer | 2.11 × 10−4 | Regulation of axonogenesis | 3.72 × 10−4 | ||
| Pathways in cancer | 5.35 × 10−4 | Regulation of cell morphogenesis involved | 4.67 × 10−4 | ||
| Apoptosis | 7.32 × 10−4 | in differentiation | |||
| Ubiquitin-mediated proteolysis | 8.74 × 10−4 | Chromatin modification | 9.76 × 10−4 | ||
| Insulin signaling pathway | 1.07 × 10−3 | Regulation of apoptosis | 1.32 × 10−3 | ||
| Renal cell carcinoma | 1.19 × 10−3 | ncRNA metabolic process | 1.80 × 10−3 | ||
| ErbB signaling pathway | 1.22 × 10−3 | 4 Hours | G protein-coupled receptor protein signaling | 4.65 × 10−4 | |
| RNA polymerase | 1.72 × 10−3 | Cell surface receptor linked signal transduction | 2.3 × 10−3 | ||
| MAPK signaling pathway | 2.31 × 10−3 | 6 Hours | ncRNA processing | 1.04 × 10−7 | |
| Prostate cancer | 2.48 × 10−3 | Mitochondrial transport | 3.10 × 10−5 | ||
| Lysine degradation | 3.23 × 10−3 | Regulation of ubiquitin-protein ligase activity | 2.69 × 10−4 | ||
| Wnt signaling pathway | 3.33 × 10−3 | ATP synthesis coupled proton transport | 4.11 × 10−4 | ||
| Pyruvate metabolism | 3.93 × 10−3 | Negative regulation of ubiquitin-protein ligase | 9.36 × 10−4 | ||
| Axon guidance | 5.50 × 10−3 | Sterol biosynthetic process | 1.25 × 10−3 | ||
| Cell cycle | 5.65 × 10−3 | 8 Hours | Negative regulation of apoptosis | 1.57 × 10−3 | |
| 6 Hours | Huntington’s disease | 5.09 × 10−8 | Negative regulation of programmed cell death | 1.80 × 10−3 | |
| Oxidative phosphorylation | 2.49 × 10−7 | ncRNA metabolic process | 2.42 × 10−3 | ||
| Alzheimer’s disease | 8.21 × 10−7 | Muscle tissue development | 2.6 × 10−3 | ||
| Pyrimidine metabolism | 1.23 × 10−5 | 24 Hours | Chromatin modification | 1.01 × 10−6 | |
| Parkinson’s disease | 4.96 × 10−5 | Mitosis | 4.04 × 10−5 | ||
| RNA polymerase | 5.42 × 10−4 | Small GTPase-mediated signal transduction | 5.60 × 10−5 | ||
| Pentose phosphate pathway | 1.37 × 10−3 | M phase of mitotic cell cycle | 7.28 × 10−5 | ||
| Purine metabolism | 2.10 × 10−3 | Protein kinase cascade | 7.79 × 10−5 | ||
| Glycosphingolipid biosynthesis | 3.04 × 10−3 | Regulation of apoptosis | 1.36 × 10−4 | ||
| Alanine and aspartate metabolism | 3.18 × 10−3 | Lipid oxidation | 1.33 × 10−3 | ||
| 24 Hours | VEGF signaling pathway | 8.92 × 10−5 | Retrograde vesicle-mediated transport | 1.43 × 10−3 | |
| Pathways in cancer | 3.51 × 10−4 | Negative regulation of cell growth | 1.67 × 10−3 | ||
| Base excision repair | 2.60 × 10−3 | Phospholipid biosynthetic process | 2.44 × 10−3 | ||
| Axon guidance | 3.45 × 10−3 | Central nervous system development | 2.50 × 10−3 | ||
| Non–small cell lung cancer | 4.47 × 10−3 | Regulation of axonogenesis | 2.79 × 10−3 | ||